Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene‑silencing effects and siRNA biodistribution in mice

Hattori,Yoshiyuki; Tamaki,Kyoko; Sakasai,Sho; Ozaki,Kei‑Ichi; Onishi,Hiraku

doi:10.3892/mmr.2020.11525

Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene‑silencing effects and siRNA biodistribution in mice

Authors:
- Yoshiyuki Hattori
- Kyoko Tamaki
- Sho Sakasai
- Kei‑Ichi Ozaki
- Hiraku Onishi
View Affiliations

Affiliations: Department of Molecular Pharmaceutics, Hoshi University, Tokyo 142‑8501, Japan, Department of Drug Delivery Research, Hoshi University, Tokyo 142‑8501, Japan, Department of Molecular Pathology, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Kyoto 610‑0395, Japan
Published online on: September 18, 2020 https://doi.org/10.3892/mmr.2020.11525
Pages: 4183-4196
Copyright: © Hattori et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polyethylene glycol (PEG)‑modifications (PEGylations) of cationic liposome/small interfering RNA complexes (siRNA lipoplexes) can enhance their systemic stability. The present study determined the effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene‑silencing effects and siRNA biodistribution after intravenous injection. Three types of dialkyl or trialkyl cationic lipids were used in the current study for the preparation of cationic liposomes. Additionally, various PEGylated siRNA lipoplexes that contained PEG‑1,2‑distearoyl‑sn‑glycero‑3‑phosphoethanolamine (DSPE), PEG‑1,2‑distearoyl‑rac‑glycero‑3‑methylpolyoxyethylene (DSG), PEG‑cholesterol (PEG‑Chol) and PEG‑chondroitin sulfate conjugate (PEG‑CS) were prepared. The results revealed that PEGylation of siRNA lipoplexes with PEG‑DSPE strongly decreased gene‑silencing effects in cells. In contrast, those with PEG‑DSG, PEG‑Chol and PEG‑CS did not largely decrease gene-silencing effects. However, regardless of the PEG‑derivative type, PEGylation of siRNA lipoplexes decreased their agglutination with erythrocytes. Furthermore, intravenous injection of PEGylated siRNA lipoplexes markedly decreased the accumulation of siRNA in the lungs, regardless of the type of PEG‑derivative. However, non‑PEGylated siRNA lipoplexes accumulated mainly in the lungs regardless of the siRNA lipoplex cationic lipid type. The results indicated that PEGylation of siRNA lipoplexes with PEG‑DSG, PEG‑Chol and PEG‑CS may improve systemic stability without losing transfection activity by PEGylation.

View Figures

View References

1	Wilson RC and Doudna JA: Molecular mechanisms of RNA interference. Annu Rev Biophys. 42:217–239. 2013. View Article : Google Scholar : PubMed/NCBI
2	Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G and Sood AK: RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 37:107–124. 2018. View Article : Google Scholar : PubMed/NCBI
3	Zhang S, Zhi D and Huang L: Lipid-based vectors for siRNA delivery. J Drug Target. 20:724–735. 2012. View Article : Google Scholar : PubMed/NCBI
4	Zatsepin TS, Kotelevtsev YV and Koteliansky V: Lipid nanoparticles for targeted siRNA delivery-going from bench to bedside. Int J Nanomedicine. 11:3077–3086. 2016. View Article : Google Scholar : PubMed/NCBI
5	Zhang Y, Satterlee A and Huang L: In vivo gene delivery by nonviral vectors: Overcoming hurdles? Mol Ther. 20:1298–1304. 2012. View Article : Google Scholar : PubMed/NCBI
6	Xia Y, Tian J and Chen X: Effect of surface properties on liposomal siRNA delivery. Biomaterials. 79:56–68. 2016. View Article : Google Scholar : PubMed/NCBI
7	Hatakeyama H, Akita H and Harashima H: The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull. 36:892–899. 2013. View Article : Google Scholar : PubMed/NCBI
8	Hattori Y, Shimizu S, Ozaki KI and Onishi H: Effect of cationic lipid type in Folate-PEG-modified cationic liposomes on folate receptor-mediated siRNA transfection in tumor cells. Pharmaceutics. 11:1812019. View Article : Google Scholar
9	Sonoke S, Ueda T, Fujiwara K, Sato Y, Takagaki K, Hirabayashi K, Ohgi T and Yano J: Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res. 68:8843–8851. 2008. View Article : Google Scholar : PubMed/NCBI
10	Song F, Sakurai N, Okamoto A, Koide H, Oku N, Dewa T and Asai T: Design of a novel PEGylated liposomal vector for systemic delivery of siRNA to solid tumors. Biol Pharm Bull. 42:996–1003. 2019. View Article : Google Scholar : PubMed/NCBI
11	Chen S, Tam YY, Lin PJ, Leung AK, Tam YK and Cullis PR: Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J Control Release. 196:106–112. 2014. View Article : Google Scholar : PubMed/NCBI
12	Nakamura T, Noma Y, Sakurai Y and Harashima H: Modifying cationic liposomes with cholesteryl-PEG prevents their aggregation in human urine and enhances cellular uptake by bladder cancer cells. Biol Pharm Bull. 40:234–237. 2017. View Article : Google Scholar : PubMed/NCBI
13	Hattori Y, Nakamura T, Ohno H, Fujii N and Maitani Y: siRNA delivery into tumor cells by lipid-based nanoparticles composed of hydroxyethylated cholesteryl triamine. Int J Pharm. 443:221–229. 2013. View Article : Google Scholar : PubMed/NCBI
14	Hattori Y, Hara E, Shingu Y, Minamiguchi D, Nakamura A, Arai S, Ohno H, Kawano K, Fujii N and Yonemochi E: siRNA delivery into tumor cells by cationic cholesterol derivative-based nanoparticles and liposomes. Biol Pharm Bull. 38:30–38. 2015. View Article : Google Scholar : PubMed/NCBI
15	Hattori Y, Arai S, Kikuchi T, Ozaki K, Kawano K and Yonemochi E: Therapeutic effect for liver-metastasized tumor by sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA. J Drug Target. 24:309–317. 2016. View Article : Google Scholar : PubMed/NCBI
16	Dawlee S, Sugandhi A, Balakrishnan B, Labarre D and Jayakrishnan A: Oxidized chondroitin sulfate-cross-linked gelatin matrixes: A new class of hydrogels. Biomacromolecules. 6:2040–2048. 2005. View Article : Google Scholar : PubMed/NCBI
17	Sasatsu M, Onishi H and Machida Y: Preparation of a PLA-PEG block copolymer using a PLA derivative with a formyl terminal group and its application to nanoparticulate formulation. Int J Pharm. 294:233–245. 2005. View Article : Google Scholar : PubMed/NCBI
18	Hattori Y, Nakamura A, Hanaya S, Miyanabe Y, Yoshiike Y, Kikuchi T, Ozaki KI and Onishi H: Effect of chondroitin sulfate on siRNA biodistribution and gene silencing effect in mice after injection of siRNA lipoplexes. J Drug Deliv Sci Tech. 41:401–409. 2017. View Article : Google Scholar
19	Hattori Y, Nakamura A, Arai S, Nishigaki M, Ohkura H, Kawano K, Maitani Y and Yonemochi E: In vivo siRNA delivery system for targeting to the liver by poly-l-glutamic acid-coated lipoplex. Results Pharma Sci. 4:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
20	Hattori Y, Yamasaku H and Maitani Y: Anionic polymer-coated lipoplex for safe gene delivery into tumor by systemic injection. J Drug Target. 21:639–647. 2013. View Article : Google Scholar : PubMed/NCBI
21	Fang Y, Xue J, Gao S, Lu A, Yang D, Jiang H, He Y and Shi K: Cleavable PEGylation: A strategy for overcoming the ‘PEG dilemma’ in efficient drug delivery. Drug Deliv. 24 (sup1):22–32. 2017. View Article : Google Scholar : PubMed/NCBI